Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3C3 | Q8NEB9 | 14/20 | 0.66 |
| ▸ | IKBKB | O14920 | 1/20 | 0.43 |
| ▸ | CHUK | O15111 | 1/20 | 0.43 |
| ▸ | PRKCI | P41743 | 2/20 | 0.42 |
| ▸ | CDC7 | O00311 | 1/20 | 0.41 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.41 |
| ▸ | CIT | O14578 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20765134 | 0.86 | PIK3C3 (0.70) | PIK3C3IKBKBCHUK | |
| SCHEMBL20765136 | 0.86 | PIK3C3 (0.67) | PIK3C3CDC7DBF4 | |
| SCHEMBL24482945 | 0.86 | PIK3C3 (0.67) | PIK3C3CDC7DBF4 | |
| SCHEMBL24482944 | 0.86 | PIK3C3 (0.67) | PIK3C3CDC7DBF4 | |
| SCHEMBL24483888 | 0.85 | PIK3C3 (0.69) | PIK3C3IKBKBCHUK | |
| SCHEMBL29669928 | 0.85 | PIK3C3 (0.69) | PIK3C3IKBKBCHUK | |
| SCHEMBL23272166 | 0.85 | PIK3C3 (0.68) | PIK3C3 | |
| SCHEMBL23891853 | 0.83 | PIK3C3 (0.52) | PIK3C3IKBKBCHUKPRKCIROCK2 | |
| SCHEMBL20765217 | 0.82 | PIK3C3 (0.53) | PIK3C3IKBKBCHUKPRKCI | |
| SCHEMBL23272162 | 0.82 | PIK3C3 (0.78) | PIK3C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250127790-A1 | COMBINATION THERAPY USING VPS34 INHIBITORS | DECIPHERA PHARMACEUTICALS, LLC | 2025-04-24 | — | — | US | claimed |
| EP-4384180-A1 | COMBINATION THERAPY OF VPS34 INHIBITORS AND STING AGONIST FOR USE IN THE TREATMENT OF CANCER | Deciphera Pharmaceuticals, LLC (US) | 2024-06-19 | — | — | EP | claimed |
| CN-118201619-A | Combination therapy of VPS34 inhibitors with STING agonists for the treatment of cancer | 德西费拉制药有限责任公司 | 2024-06-14 | — | — | CN | claimed |
| CN-117241800-A | Antiviral Activity of VPS34 inhibitors | 德西费拉制药有限责任公司 | 2023-12-15 | — | — | CN | claimed |
| US-20230322772-A1 | AZAINDOLYLPYRIDONE AND DIAZAINDOLYLPYRIDONE COMPOUNDS | SPRINT BIOSCIENCE AB (SE) | 2023-10-12 | — | — | US | claimed |
| EP-4251156-A1 | ANTI-VIRAL ACTIVITY OF VPS34 INHIBITORS | Deciphera Pharmaceuticals, LLC (US) | 2023-10-04 | — | — | EP | claimed |
| CN-111247144-B | Azaindolylpyridone compounds and diazaindolylpyridone compounds | 思普瑞特生物科学公司 | 2023-04-28 | — | — | CN | claimed |
| WO-2023019259-A1 | COMBINATION THERAPY OF VPS34 INHIBITORS AND STING AGONIST FOR USE IN THE TREATMENT OF CANCER | DECIPHERA PHARMACEUTICALS, LLC (US) | 2023-02-16 | — | — | WO | claimed |
| US-11498919-B2 | Azaindolylpyridone and diazaindolylpyridone compounds | SPRINT BIOSCIENCE AB (SE) | 2022-11-15 | — | — | US | claimed |
| US-20220184054-A1 | ANTI-VIRAL ACTIVITY OF VPS34 INHIBITORS | DECIPHERA PHARMACEUTICALS, LLC | 2022-06-16 | — | — | US | claimed |
| WO-2022115543-A1 | ANTI-VIRAL ACTIVITY OF VPS34 INHIBITORS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2022-06-02 | — | — | WO | claimed |
| EP-4001278-A1 | AZAINDOLYLPYRIDONE AND DIAZAINDOLYLPYRIDONE COMPOUNDS | Sprint Bioscience AB (SE) | 2022-05-25 | — | — | EP | claimed |
| EP-3672967-B1 | AZAINDOLYLPYRIDONE AND DIAZAINDOLYLPYRIDONE COMPOUNDS | SPRINT BIOSCIENCE AB (SE) | 2021-10-06 | — | — | EP | claimed |
| US-20210122745-A1 | AZAINDOLYLPYRIDONE AND DIAZAINDOLYLPYRIDONE COMPOUNDS | SPRINT BIOSCIENCE AB (SE) | 2021-04-29 | — | — | US | claimed |
| CN-111247144-A | Azaindolylpyridinone compounds and diazaindolylpyridinone compounds | 思普瑞特生物科学公司 | 2020-06-05 | — | — | CN | claimed |
| US-20250127790-A1 | COMBINATION THERAPY USING VPS34 INHIBITORS | DECIPHERA PHARMACEUTICALS, LLC | 2025-04-24 | — | — | US | disclosed |
| EP-4384180-A1 | COMBINATION THERAPY OF VPS34 INHIBITORS AND STING AGONIST FOR USE IN THE TREATMENT OF CANCER | Deciphera Pharmaceuticals, LLC (US) | 2024-06-19 | — | — | EP | disclosed |
| EP-3672967-A1 | AZAINDOLYLPYRIDONE AND DIAZAINDOLYLPYRIDONE COMPOUNDS | Sprint Bioscience AB (SE) | 2020-07-01 | — | — | EP | disclosed |
| CN-111247144-A | Azaindolylpyridinone compounds and diazaindolylpyridinone compounds | 思普瑞特生物科学公司 | 2020-06-05 | — | — | CN | disclosed |
| WO-2019038384-A1 | AZAINDOLYLPYRIDONE AND DIAZAINDOLYLPYRIDONE COMPOUNDS | SPRINT BIOSCIENCE AB (SE) | 2019-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250127790-A1 | COMBINATION THERAPY USING VPS34 INHIBITORS | STING1, TBK1, VPS4B | PIK3C3 1649/4885IKBKB 585/4885CHUK 1499/4885 |
| US-20230322772-A1 | AZAINDOLYLPYRIDONE AND DIAZAINDOLYLPYRIDONE COMPOUNDS | AZI2, IAPP, ZFX | PIK3C3 1407/4885IKBKB 2349/4885CHUK 1469/4885 |
| US-20220184054-A1 | ANTI-VIRAL ACTIVITY OF VPS34 INHIBITORS | SARS1, VPS26B, VPS4B | PIK3C3 1967/4885IKBKB 785/4885CHUK 1309/4885 |
| US-20210122745-A1 | AZAINDOLYLPYRIDONE AND DIAZAINDOLYLPYRIDONE COMPOUNDS | AZI2, IAPP, ZFX | PIK3C3 1407/4885IKBKB 2349/4885CHUK 1469/4885 |
| US-11498919-B2 | Azaindolylpyridone and diazaindolylpyridone compounds | AZI2, IAPP, ZFX | PIK3C3 1407/4885IKBKB 2349/4885CHUK 1469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.